Antiproliferative activity of β-hydroxy- β-arylalkanoic acids by Dilber, Sanda P. et al.
Int. J. Mol. Sci. 2007, 8, 214-228 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
© 2007 by MDPI 
www.mdpi.org/ijms/ 
 
Antiproliferative Activity of β-Hydroxy-β-Arylalkanoic Acids 
Sanda P. Dilber 1, Željko S. Žižak 2,Tatjana P. Stanojković 2, Zorica D. Juranić 2, Branko J. 
Drakuli ć 3 and Ivan O. Juranić 4 * 
1 Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia; E-Mail: 
sandad@pharmacy.bg.ac.yu 
2 Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia; E-Mails: 
zizakz@ncrc.ac.yu; stanojkovict@ncrc.ac.yu; juranicz@ncrc.ac.yu 
3 Department of Chemistry, Institute of Chemistry, Technology and Metallurgy, Njegoševa 12, 11000 
Belgrade, Serbia; E-Mail: bdrakuli@chem.bg.ac.yu 
4 Faculty of Chemistry, University of Belgrade, P.O. Box 158, 11001 Belgrade, Serbia; E-Mail: 
ijuranic@chem.bg.ac.yu 
* Author to whom correspondence should be addressed. 
Received: 13 February 2007 / Accepted: 5 March 2007 / Published: 13 March 2007 
 
Abstract: Article describes the synthesis of fifteen β-hydroxy-β-arylalkanoic acids by 
Reformatsky reaction using the 1-ethoxyethyl-2-bromoalkanoates, aromatic or cycloalkyl 
ketones or aromatic aldehydes. The short survey of previously reported synthetic procedures 
for title compounds, is given. The majority of obtained compounds exert antiproliferative 
activity in vitro toward human: HeLa, Fem-X cells, K562, and LS174 cells, having IC50 
values from 62.20 to 205 µM. The most active compound is 3-OH-2,2-di-Me-3-(4-
biphenylyl)-butanoic acid, having the IC50 value 62.20 µM toward HeLa cells. Seven 
examined compounds did not affect proliferation of healthy human blood peripheral 
mononuclear cells (PBMC and PBMC+ PHA), IC50 > 300 µM. The preliminary QSAR 
results show that estimated lipophilicity of compounds influences their antiproliferative 
activity in the first place. The ability of dehydration, and the spatial arrangement of 
hydrophobic portion, HBD and HBA in molecules are has almost equal importance as 
lipophilicity. 
Keywords: β-hydroxy-β-arylalkanoic acids, Reformatsky reaction, antiproliferative activity, 
human dedifferentiate cells, QSAR 
 




1. Introduction  
Cyclooxygenases (COX) or prostaglandin endoperoxide synthases (PGHS) are the key enzymes in 
the synthesis of prostaglandins from their precursor, arachidonic acid. 
Arachidonic acid is cleaved from cell membrane phospholipids by phospholipase A2. The COX-1 
or COX-2 converts arachidonic acid in unstable endoperoxides PGG2 and PGH2 that are subsequently 
metabolized by synthases to primary prostaglandins PGD2, PGE2, PGF2a, TXA2 (Tromboxane A2) 
and PGI2 (Prostacycline).  Prostaglandins are the lipid mediators made by most cells in the body, 
except for red blood cells, and they are released by almost any type of chemical or mechanical stimulus 
[1]. The two definitely known isoforms, COX-1 and COX-2, show distinct expressions patterns and 
distinct biological activities.  
The COX-1 is built in many different cells to create prostaglandins used for basic “housekeeping” 
messages throughout the body. COX-1 is a constitutively expressed protein that is responsible for the 
physiological production of prostaglandins  [2]. The COX-2 is built only in special cells and is used for 
signaling pain and inflammation. This isoform is also called inducible isoform of enzime COX [3]. In 
inflammatory process COX-2 is overexpressed. The COX-1 variant protein, named COX-3, is sensitive 
to inhibition with paracetamol. 
Main therapeutic actions of NSAID-s (nonsteroidal anti-inflammatory drugs) are analgesic, 
antipyretic and anti-inflammatory. Recently was reported that some of NSAIDs (Diclofenac, Naproxen, 
Etodolac, …)  were investigated as antiproliferative agents [4]. 
We have synthesized fifteen β-hydroxy-β-arylalkanoic acids that are structurally similar to COX 
inhibitors: p-isobutylphenylacetic acid (Ibufenak) [5], 4-biphenylacetic acid (Felbinac) [6], α-(4-
isobutylphenyl)propanoic acid (Brufen) [7], α-(6-methoxy-2-naphtyl)propanoic acid (Naproxen) [8].  
Introducing the oxo-functionality in position four of 4-biphenylylbutanoic acid increases their anti-
inflammatory activity (Fenbufen) [9]. Our compounds belong to the class of aryl- and 
cycloalkylpropanoic acids, structurally similar with commercially available NSAID-s. Their anti-
proliferative activity toward malignant cell lines was evaluated in this work. With the aim to determine 
the undesirable cytotoxic effect of investigated compounds on immune competent cells the normal 
peripheral blood mononuclear cells were used as target cells, too. 
There are several pathways in direct synthesis of β-hydroxy acids. The careful control of the 
conditions used for the hydrolysis can suppress the dehydration, and good yield of some hydroxy acids 
have been reported [10]. In accordance with the literature, β-hydroxy acids could be produced through 
Reformatsky reaction by using tert-butyl [10], trimethylsilyl [11],  or tetrahydropyranyl [12]  esters as 
starting materials, which provide mild acidic conditions. This approach is commonly known as 
modified Reformatsky reaction for direct synthesis of β-hydroxy acids. Another method for direct 
synthesis β-hydroxy acids can be used when α-bromo acid is not accessible, and utilizes the dianion of 
carboxylic acids obtained by the reaction between acids and extremely strong bases as Li-
diisopropylamide, instead of Reformatsky reagent [13].  In this reaction carboxylic proton and α-
hydrogen are both substituted by lithium. The class of substituted α-phenyl-β-hydroxypropanoic acids 
was obtained in this way. 
It has been shown that the carboxyl group of α-bromo acids can be protected by allyl-zincbromide. 
The obtained bromozinc salt undergoes the Reformatsky reaction [14]. This method is applicable to α-




bromo acids having a bromine atom on secondary or tertiary carbon. In case of bromoacetic acid this 
method is ineffective.  
A method for direct preparation of β-hydroxy acids using corresponding halomagnesium salts of α-
bromo acids instead of α-bromo esters, was described [15]. Ethyl-vinyl esters can be used instead of 2-
tetrahydropyranyl esters as intermediates in Reformatsky reaction [16,17]. 
Readily accessible α-bromo ester-acetals, obtained by the action of aliphatic vinyl ethers on α-
bromo acids, can be used in the Reformatsky reaction for direct preparation of β-hydroxy acids [16,17]. 
The authors who reported these syntheses did not report full physicochemical characterization of 
obtained compounds. 
In our work we have synthesized these compounds using previously described methods [16,17]. All 
compounds were characterized by their melting points, MS, IR, 1H, and 13C NMR spectra, and by 
elemental analysis, as well. 
2. Results and Discussion  
2.1. Antiproliferative activity 
In our previous communications the antiproliferative activity of β-hydroxy-β-arylalkanoic acids was 
reported [20-21]. Antiproliferative activity of studied compounds (1-15) was assessed using Kenacid 
Blue R dye binding method, as described in literature [19]. Concentrations of examined compounds (1-
15) that induced the 50% decrease of survival (S) of HeLa, Fem-X, K562, and LS174 cells (IC50), 
obtained from graph (S%)=f(c) are given in Table 1. IC50 Of known cytostatic drug, cis-
diammindichloroplatinum (cis-DDP) was used as positive control. Seven examined compounds 
1,3,4,7,10-12 did not affect proliferation of healthy human blood peripheral mononuclear cells (PBMC 
and PBMC + PHA) IC50 > 300 µM. 
All the studied compounds, except compound 15, affected the survival of HeLa cells, while 
compound 3 affected the survival of all four examined cell lines. The most active compound toward 
HeLa cells is compound 1, while the least active one is compound 14. Figure 1 shows light microscopy 
of four target cell lines after treatment for 72 h with medium alone (control), or with 150 µM of 
compound 1. 




Table 1.  Structures and IC50 values of studied β-hydroxy-β-arylalkanoic acids toward HeLa, Fem-X, 







 IC50 (µM) 
No R1- R2- R3- R4- HeLa Fem-X K562 LS174 
1 Me- Me- Me- Ph-Ph- 62.20 205 141 154 
2 Me- Me- Ph- Ph- 80.56 / / / 
3 Me- H- H- 2-Cl-Ph- 97.20 89 92 93 
4 H- H- Me- Ph-Ph- 98.70 >200 >200 >200 
5 Me- Me- fluorenyl- 99.07 / / / 
6 Me- H- Ph- Ph- 99.41 / / / 
7 Me- Me- H- 4-Cl-Ph- 106.30 >200 >200 >200 
8 H- H- H- 2-Cl-Ph- 117.80 >200 >200 >200 
9 Me- Me- Me- 4-MeO-Ph- 125.80 136 >200 >200 
10 Me- Me- cyclohexyl- 128.40 >200 >200 >200 
11 Me- Me- Me- Ph- 133.17 / / / 
12 H- H- Me- 4-i-Bu-Ph- 151.40 >200 >200 >200 
13 Me- Me- H- Ph- 164.88 / / / 
14 H- H- Ph- Ph- 182.55 / / / 
15 H- Et- cyclohexyl- >200 >200 / / 




Figure 1.  Light microscopy of four studied cell lines after treatment for 72 h with medium alone 
(control, upper row), or with 150 µM of compound 1 (bottom row). Cells were observed using an 
inverted microscope and photographed by a digital camera (Olympus C-4040 Zoom). 





The QSAR study was performed using estimated lipophilicity (logP) and indicator variable I, which 
cumulatively represents the mutual arrangement of hydrogen bond donors (HBD), hydrogen bond 
acceptors (HBA) and hydrophobic area within molecules. A QSAR study of antiproliferative activity 
toward HeLa cells, against which compounds 1-14 are active, results with two-parameter correlation: 
 
log(1/IC50) = + 0.167 (±0.043) logP – 0.154 (±0.051) I– 2.527 (±0.12) 
(n = 14; r = 0.941; s = 0.046; F= 42.467; Q² = 0.810; sPRESS = 0.059) 
(1)                       
 
LogP = log (KOW) values were estimated by the Crippen fragmentation method [22]. Indicator 
variable, I, bearing value 1 for compounds having H on α carbon, and implicitly are prone for the 
dehydration, i.e., loosing hydroxyl functionality (HBD) in position near the aromatic moiety. Indicator 
variable bearing value –1 was ascribed to compounds which have ortho substituent(s) on the aryl (or 
cycloalkyl) moiety, that stericaly hinders their coplanarity with C-OH bond.  In this way it accounts for 
changed electronic environment of oxygen atom - influencing the HBD ability of β-OH group. 
Inclusion of indicator variable I is a reminiscent of classical Free-Wilson approach [23], that imply 
factorization of differences on distinct position of molecules in separate groups, and posterior multiple 
regression analysis of obtained matrix. Two distinct structural features were described by one indicator 
variable in order to obtain statistics of higher quality.  
Table 2.  Descriptors used in QSAR, obtained and from Equation 1 predicted log(1/(IC50)) values for 
HeLa cells. 
No logP I Obtained log(1/(IC50)) Predicted log(1/(IC50)) 
1 4.16 0 –1.794  –1.833  
2 3.88 0 –1.906  –1.880  
3 2.12 –1 –1.988  –2.020  
4 2.89 0 –1.994  –2.045  
5 3.53 0 –1.996  –1.938  
6 3.18 0 –1.997  –1.997  
7 2.83 0 –2.027  –2.055  
8 1.56 –1 –2.071  –2.113  
9 2.36 0 –2.100  –2.133  
10 1.99 –1 –2.109  –2.041  
11 2.49 0 –2.124  –2.112  
12 2.87 1 –2.180  –2.202  
13 2.27 0 –2.217  –2.148  
14 2.61 1 –2.261  –2.246  
 
By using only logP values, the good correlation could be obtained for compounds 1, 2, 5, 12 and 14 
(r = 0.997), while something inferior one (r = 0.858) by additional inclusion of 4, 6, 7, 9, 11 and 13.    




After the energy minimization using molecular mechanics (MM+ force field), the similarity search 
was performed using VegaZZ 2.0.5 software [24]. Superimposition of molecular structure details 
(phenyl rings linked [25] to C-OH (β-OH group), C-OH and carboxyl carbonyl) of compounds 2 – 14 
upon the structure of the most active one (1), and posterior correlation of root mean square deviation 
(RMSD) of considered atoms positions with activity and indicator variable I (I as defined above), gives 
low intercorrelation coefficients: activity/RMSD, r = 0.61 while for I/RMSD, r = 0.69. This shows that 
assumptions used for introduction of I (as defined above) are well chosen. 
 
Figure 2.  Correlation of predicted (from Eq. 1) and experimentally obtained log(1/(IC50) values for 
HeLa cells (n = 14; r= 0.941) 
 Values of used descriptors, obtained, and from the Equation 1 predicted log(1/(IC50)), are given in 
Table 2. The relationship between obtained vs. predicted log(1/(IC50)) in graphical form are given in 
the Figure 2. The higher weight descriptor in correlation is the estimated logP, while indicator variable 
that describes the stereoelectronic demands for the activity has a comparable weight. 
2.3. Conclusion 
The majority of synthesized β-hydroxy-β-arylalkanoic acids exert antiproliferative activity n vitro 
toward HeLa, Fem-X, K562 and LS174 having IC50 values from 62.20 to 205 µM. The most active 
compound is 3-hydroxy-2,2-dimethyl-3-(4-biphenylyl)butanoic acid. Seven examined compounds did 
not affect proliferation of healthy human blood peripheral proliferation of healthy human blood 
peripheral mononuclear cells (PBMC and PBMC+PHA), IC50 > 300 µM. 
The presence of COX in HeLa cells is documented [26].   It could explain the higher sensitivity of 
HeLa cell line to our compounds.  




A QSAR study of antiproliferative activity toward HeLa cells, against which compounds 1-14 are 
active indicate that estimated lipophilicity of compounds influences their antiproliferative activity in 
the first place, and indicate that spatial arrangement of HBD and HBA (exerted by indicator variable) 
has a comparable importance. 
3. Experimental 
Aromatic ketones, aromatic aldehydes, α-bromo acids and ethyl-vinyl ether were reagent grade nd 
were purchased from Sigma-Aldrich or Fluka.  Zinc powder was activated by treatment with conc. 
hydrochloric acid, subsequently washed with distilled water, ethanol, acetone and ether, dried for 2 
hours at 120 ºC and finally dried in the presence of CaCl2 under the reduced pressure. Tetrahydrofuran 
was purified by treatment with LiAlH4 (LAH), distilled in the presence of the excess of LAH and used 
immediately after the distillation. For the synthesis of α-bromo esters-acetals, dry, thiophene-free, 
benzene was used. All other solvents were p.a. grade. 
IR Spectra were taken in KBR pellet on Perkin-Elmer 1725 spectrophotometer.  1H and 13C nuclear 
magnetic resonance (NMR) spectra were recorded at 200/50 MHz with tetramethylsilane (TMS) as 
internal standard on a Varian “Gemini 200” spectrometer in CDCl3.  The mass spectra were taken on a 
Finnigan-MAT 8230 BE MS, employing both chemical ionization (i-C4H10) (CI), and electron impact 
(70 eV) (EI). The elemental analyses were done on Elemetar-Vario EL III equipment. Melting points 
were determined in open capillary tubes on Büchi apparatus and are uncorrected. 
3.1. Syntheses 
Compounds 1-15 were synthesized by two-step reaction. In the first phase (Scheme 1) the 
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R2= H-, Me-, Et-
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Scheme 1. Synthesis of α-bromo esters-acetals (Phase I)  
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Scheme 2. Synthesis of β-hydroxy-β-arylalkanoic acids (Phase II) 
 
The second phase was the modified Reformatsky reaction - reaction between previously synthesized 
intermediates and suitable aldehydes or ketones in presence of Zn in tetrahydrofuran (THF) at –5 °C
during the first few hours, followed by subsequent rising to the room temperature (Sch me 2). The β-
hydroxy-β-aryl, or β-cycloalkylalkanoic acids (1-15) were obtained (Table 1). 
 
 3.1.1 Synthesis of α-bromo esters-acetals (Scheme 1, Phase I).  
In a 100 ml two-necked round bottom flask equipped with CaCl2 tube, argon inlet and magnetic 
stirrer, the α-bromo acid (0.03 mol), ethyl-vinyl ether (3.37 g, 5.00 ml, ~ 0.05 mol), 4-6 ml dry benzene 
were placed, and stirred at room temperature for 2 hours. After the evaporation of benzene and excess 
of ethyl-vinyl ether, the residual mixture was distilled under the reduced pressure. In this way obtained 
esters were analyzed immediately by instrumental methods. By the longer staying at room temperature, 
or even on the lower temperatures (~4 °C), obtained esters become yellow, probably due to 
decomposition. The boiling points of synthesized compounds were determined during distillation. The 
compounds were characterized by elemental analyses, MS, IR, 1H, and 13C NMR spectroscopy. The 
bromoethyl-vinyl ester of bromoethanoic acid, synthesis of which is previously reported [18] was 
characterized only by spectral data. These intermediates are labeled as PI-1 to PI-4, being result of 
Phase I synthesis. 
According to procedure 3.1.1, the following intermediate compounds were synthesized: 
PI-1. 1-Ethoxyethyl-2-bromopropanoate: C7H13O3Br; Mw = 225.02; Boiling point:  87 
0C, (3 mm 
Hg); IR (Film) : ν max (cm-1) 2984, 2935, 1738 (ν  >C=O), 1139 cm-1(ν  -C-O-C-); 1H NMR (CDCl 3) 
(δ): 1.22 (t, J 7.1 Hz, 3H); [1.23 (t, J 7.1 Hz, 3H)]; 1.43 (d, J5.2 Hz, 3H); [1.44 (d, J 5.2 Hz, 3H)]; 1.82 
(d, J 6.9 Hz, 3H); 3.5-3.89 (m, 4H); 4.38 (q, J 7.00 Hz; 2H); 5.97 (q, J 5.2 Hz; 2H); 13C NMR (CDCl 3) 
(δ): δ 14.78 (O-CH-CH3); 20.23 [20.45] (CH2-CH3); 21.16 [21.33] (Br-CH-CH3); 40.02 [40.31] (Br-
CH- CH3); 64.37 [64.76] (O-CH2-); 97.66 [97.96] (O-CH-O); 169.71 169.76 (C=Oester); MS (CI):  225 
M+, 223, 207 (M-18), 52 (M-73), 144 (M-80); Yield (%): 68; Elemental analysis (%): Calc. C, 37.35 
H, 5.82; Found C, 37.16 H, 5.83. 




PI-2. 1-Ethoxyethyl-2-bromobuthanoate: C8H15O3Br; Mw = 239.11; Boiling point: 60 
0C (1 mm 
Hg); IR (Film) : ν max (cm-1) 2978, 2939, 1737 (ν , >C=O), 1137 (ν  -C-O-C-); 1H NMR (CDCl 3) (δ): 
1.04 (t, J 7.4 Hz, 6H); 1.21 (t, J 7.1 Hz, 6H); 1.45 (d, J 5.0 Hz, 6H)]; 1.97-2.21 (m, 4H); 3.51-3.85 (m, 
4H); 4.16 (t, J 7.0 Hz, 1H); [4.17 (t, J 7.0 Hz, 1H)]; 5.98 (q, J 5.4 Hz, 2H); 13C NMR (CDCl 3) (δ): 
11.51 (Br-CH-CH2-CH3); 14.68 (-O-CH2-CH3); 20.18 [20.36] (CH3CH(OEt)-O); 27.82 [27.93] (Br-
CH-CH2-CH3); 47.47 [47.67] (Br-CH-); 64.60 (-O-CH2-CH3); 97.66 [97.72] (CH3CH(OEt)-O); 169.02 
(169.14) (C=Oester).; MS (CI):  239 (M
+), 241, 167 (M-73).; Yield (%): 81; Elemental analysis (%): 
Calc. C, 40.18; H ,6.32; Found C, 40.47; H, 6.50. 
The compounds 1 and 2 are the distereomeric mixtures.  In proton NMR spectra, the shift values 
attributed to the minor diasteromer are given in square brackets.  
PI-3. 1-Ethoxyethyl-2-bromo-2-methylpropanoate: C8H15O3Br; Mw = 239.11; Boiling point:  94 
0C, 20 mm Hg; IR (Film) : ν  max (cm-1) 2982, 2932, 1732 (ν , >C=O), 1140 (ν  -C-O-C-); 1H NMR 
(CDCl3) (δ): 1.23 (t, J 7.0 Hz, 3 H); 1.45 (d, J 5.4 Hz; 3 H); 1.94 (s, 6 H); 3.51-3.88 (m; 2 H); 5.97 (q, 
J 5.2 Hz, 1H); 13C NMR (CDCl 3) (δ): 14.86 (-O-CH2-CH3); 20.29 (CH3CH(OEt)-O); 30.37 (Br-
C(CH3)2-); 55.86 (Br-C(CH3)2-); 64.76 (-O-CH2-CH3); 98.12 (CH3CH(OEt)-O); 171.16 (C=Oester).; 
MS (CI):  240 (M+H)+, 169 (M-73); Yield (%): 54; Elemental analysis (%): Calc.: C, 40.18; H, 6.32. 
Found: C, 40.14; H, 6.57. 
PI-4. 1-Ethoxyethyl-2-bromoethanoate: C6H11O3Br; Mw = 211.05; Boiling point:  85 
0C (3 mm 
Hg); IR (Film) : ν max (cm-1) 2983, 2937, 1734 (ν , >C=O), 1285 (ν , >C-O), 1129 (ν  -C-O-C-); 1H 
NMR (CDCl 3) (δ): 1.22 (t, J 7 Hz, 3 H); 1.44 (d, J 5 Hz, 3 H); 3.5-3.91 (m, 2 H); 3,85 (d, J 1.6 Hz, 
2H); 5.97 (q, J 5.2 Hz, 1 H); 13C NMR (CDCl 3) (δ): 14.86 (-O-CH2-CH3); 20.57 (CH3CH(OEt)-O); 
26.06 (Br-CH2-); 64.98 (-O-CH2-CH3); 98.43 (CH3CH(OEt)-O); 166.97 (C=Oester); MS (EI):  168 (M-
45), 121 (M-89), 82 (Br); Yield (%): 71.  
 
3.1.2. Synthesis of β-hydroxy-β-arylalkanoic acids (Scheme 2, Phase II) 
In 100 ml three-necked, round-bottom flask, equipped with CaCl2 tube, argon inlet and magnetic 
stirrer, the Zn (0.02 mol, 1.30 g), aldehyde or ketone (0.01 mol), 40 ml of dried THF, small amounts of 
HgCl2 and I2 are placed.  Previously prepared esters (0.02 mol) were added from dropping funnel 
during 30 min under the argon atmosphere. The reaction mixtures were cooled in ice bath and 
constantly stirred magnetically, until whole amount of Zn was disappeared (10 - 48 h usually) [27]. The 
THF was removed under reduced pressure followed by addition of 30 ml of benzene and 10 ml of cold 
3M HCl. This reaction mixture was cooled at 0 °C in ice bath, and stirred for ~3 hours. The organic 
layers were taken. Obtained aqueous solutions were additionally extracted with benzene. The combined 
organic extracts were treated with 10% aqueous KHCO3 until pH ~8 was reached (hydroxy acids were 
converted in potassium salts). Alkaline aqueous solutions were extracted by small amount of ether to 
remove unreacted aldehyde or ketone. This solution was cooled at 0 °C and cold 10% HCl was 
carefully added to pH~2.5, yielding β-hydroxy acids, mostly as oil at first, turning into crystals by 
prolonged keeping on the low temperatures. In this way obtained acids were recrystallized from 
benzene or i-PrOH. 
1. 3-Hydroxy-2,2-dimethyl-3-(4-biphenylyl)butanoic acid: C18H20O3; Mw = 284.35; Melting 
point:  142 0C; IR (KBr) : ν max (cm-1) 3513 (ν ,-CH-OH), 3034 (ν ,-C(O)-OH), 2977, 1688 (ν , 




>C=O), 1238 (ν , -C-O); 1H NMR (CDCl 3) (δ): 1.17 (s, 3 H); 1.20 (s, 3 H); 1.69 (s, 3 H); 7.31-7.63 
(m, 9 H); 13C NMR (CDCl3) (δ): 21.65 (-C(CH3)2-); 25.10 (-C(OH)CH3-); 50.05 (-C(CH3)2-); 77.36 (-
C(OH)CH3-); 126.07 (o-Ph); 126.98 (o’-Ph); 127.31 (p’-Ph); 127.63 (m-Ph); 128.74 (m’-Ph); 139.94 
(pipso-Ph); 140.47 (Cipso’-Ph); 141.63 (Cipso-Ph); 182.91 (COOH); MS (CI): 285 (M+H)
+, 267 (M-17), 
197 (M-87); Yield (%): 32; Elemental analysis (%): Calc.: C, 76.03; H, 7.09. Found: C, 75.57; H, 
7.28. 
2. 3-Hydroxy-2,2-dimethyl-3,3-diphenylpropanoic acid; C17H18O3; Mw = 270.32; Melting point: 
162 0C; IR (KBr ): ν max (cm-1) 3570 (ν ,-CH-OH), 3520 (ν ,-C(O)-OH), 1678 (ν , >C=O), 1160 (ν , -
C-O); 1H NMR ( CDCl 3) (δ): 1.35 (s, 6H); 7.13-7.47 (m, 10 H, after the subtraction of CHCl3 signal at 
7.263 δ); 13C NMR (CDCl 3) (δ): 23.93 (-C(CH3)2-); 48.71 (-C(CH3)2-); 82.44 (C-OH); 127.25 (o-Ph); 
127.39 (p-Ph); 128.63 (m-Ph); 144.62 (Cipso-Ph); 185.24 (COOH); MS (CI):  253 (M-17), 183 (M-87); 
Yield (%): 40; Elemental analysis (%): Calcd.: C, 75.53; H, 6,71. Found: C, 75.22; H, 6,74. 
3.  3-Hydroxy-2-methyl-3-(2-chlorophenyl)propanoic acid; C10H11ClO3; Mw = 214.65; Melting 
point: 84 0C; IR (KBr):  ν max (cm-1) 3325, 3420 (ν ,-CH-OH), 3057, 2992 (ν ,-C(O)-OH), 1707 (ν , 
>C=O), 1232 (ν , -C-O-); 1H NMR (CDCl 3) (δ): 1.09 (d, J 7.2 Hz, 3 H, after the subtraction of CHCl3 
signal at 7.263 δ); 1.16 (d, J 7.2 Hz, 3 H); 2.88-3.11 (m, 1 H); 5.31(d, J 8 Hz, 1 H); 5.62 (d, J 2.2 Hz, 1 
H); 7.18-7.63 (m, 4 H); 13C NMR (CDCl 3) (δ): 9.14 (14.15) (-CH(CH3)-); 42.55 (46.45) (-CH(CH3)-); 
69.68 (71.99) (-CH(OH)-); 126.74 (127.34) (m-Ph); 127.91 (128.23) (m-Ph); 128.73 (p-Ph); 129.16 
(129.44) (o-Ph); 129.52 (131.29) (C-Cl); 138.14 (Cipso-Ph); 181.15 (181.66) (COOH); (MS (EI):  214 
(M+),142 (M-73), 77; Yield (%): 25; Elemental analysis (%): Calcd.: C, 55.96; H, 5.17. Found: C, 
55.41; H, 5.02. 
4.  3-Hydroxy-3-(4-biphenylyl)butanoic acid; C16H16O3; Mw = 256.30; Melting point: 136 
oC; 
IR (KBr):  ν max (cm-1) 3521 (ν ,-CH-OH), 2977 (ν ,-C(O)-OH), 1689 (ν , >C=O), 1238 (ν , -C-O-); 
1H NMR (CDCl 3) (δ): 1.58 (s, 1 H); 2.96 (dd, J1 J2 16.4 Hz; 2 H); 5.63 (s, OH); 7.30-7.60 (m, 9 H); 
13C NMR (CDCl 3) (δ): 30.57 (CH3); 47.92 (-CH2-); 72.70 (C-OH); 124.85 (o-Ph); 127.10 (o’-Ph); 
127.14 (o- and p’-Ph); 127.32 (m’-Ph); 128.78 (m-Ph); 139.98 (pipso-Ph); 140.58 (Cipso’-Ph); 145.40 
(Cipso-Ph); MS (EI):  256 (M
+), 238 (M-18), 197 (M-59), 153; Yield (%): 27; Elemental analysis 
(%): Calcd.: C, 74.98; H, 6.29. Found: C, 74.70; H, 6.48. 
5. 2-[9-(9-Hydroxyfluorenyl)]-2-methylpropanoic acid; C17H16O3; Mw = 268.31; Melting point: 
138 oC; IR (KBr):  ν max (cm-1) 3387 (ν , -CH-OH), 2984 (ν ,-C(O)-OH), 1725 (ν , >C=O), 1156 (ν , -
C-O); 1H NMR (CDCl 3) (δ): 1.07 (s, 6H); 7.19-7.61 (m, 8 H); 13C NMR (CDCl3) (δ): 20.98 (-
C(CH3)2-); 48.72 (-C(CH3)2-); 85.39 (C-OH); 119.97 (m-Ph); 124.14 (m-Ph); 127.80 (p-Ph); 129.45 (o-
Ph); 140.43 (Cipso-Ar); 145.69 (Cipso); 180.65 (COOH); (MS (CI):  268 (M
+), 251 (M-17), 223 (M-45), 
181 (M-87); Yield (%): 20; Elemental analysis (%): Calcd.: C, 76.10; H, 6.01. Found: C, 76.19; H, 
6.19. 
6.  3-Hydroxy-2-methyl-3,3-diphenylpropanoic acid; C16H16O3; Mw = 256.30; Melting point: 
180 oC; IR (KBr):  ν max (cm-1) 3525 (ν , -CH-OH), 2991 (ν , -C(O)-OH), 1677 (ν , >C=O), 1225 (ν , -
C-O); 1H NMR (CDCl 3) (δ) : 1.19 (d, J 7.2 Hz, 3 H); 3.65 (q, J 7.2 Hz, 1 H); 7.13-7.56 (m, 10 H); 13C 
NMR (CDCl 3) (δ) 13.04 (CH3); 46.41 (-CH(CH3)-); 77.91 (C-OH); 125.30 (o- and o’-Ph); 126.71 (m-
Ph); 127.12 (m’-Ph); 128.18 (p- and p’-Ph); 128.47 (o- and o’-Ph); 143.80 (Cipso); 147.15 (Cipso’); 




182.04 (COOH); MS (CI):. 257 (M+H)+, 239 (M-17), 183 (M-73); Yield (%): 35; Elemental analysis 
(%): Calcd.: C, 74.98; H, 6.29. Found: C, 75.08; H, 6.11. 
7. 3-Hydroxy-2,2-dimethyl-3-(4-chlorophenyl)propanoic acid; C11H13ClO3; Mw = 228.67; 
Melting point: 142 oC; IR (KBr):  ν max (cm-1) 3501 (ν , -CH-OH), 2989 (ν , -C(O)-OH), 1683 (ν , 
>C=O), 1167 (ν , -C-O); 1H NMR (CDCl 3) (δ) : 1.13 (s, 3 H); 1.15 (s, 3 H); 4.94 (s, 3 H); 7.25-7.36 
(m, 4 H); 13C NMR (CDCl 3) (δ) 18.34 (CH3); 23.05 (CH3); 47.50 (-C(CH3)2-); 77.64 (-CH(OH)-); 
128.07 (m-Ph); 129.07 (o-Ph); 137.96 (Cipso); 183.08 (COOH); MS (CI) 229 (M+H)
+, 211 (M-18), 
141; Yield (%): 40; Elemental analysis (%): Calcd.: C, 57.78; H, 5.73. Found: C, 57.73; H, 5.75. 
8.  3-Hydroxy-3-(2-chlorophenyl)propanoic acid; C9H9ClO3; Mw = 200.62; Melting point: 92 
oC; IR (KBr):  ν max (cm-1) 3476, 3311 (ν , -C(O)-OH), 1709 (ν , >C=O), 1164 (ν , -C-O); 1H NMR 
(CDCl3) (δ): 2.71 (dd, J 9.8 Hz, J 16.8 Hz, 1H); 2.97 (dd, J 2.6 Hz, J 16.8 Hz, 1H); 5.53 (dd, J 2.2 Hz, 
J 8 Hz, 1H); 6.51 (s, OH) 7.19-7.64 (m, 4 H); 13C NMR (CDCl 3) (δ): 41.29 (-CH2-); 66.91 (-CH(OH)-
); 126.96 (m-Ph); 127.32 (p-Ph); 128.98 (m-Ph); 129.49 (o-Ph); 131.38 (C-Cl); 139.45 (Cipso); 177.57 
(COOH); MS (CI) 201 (M+), 183 (M-18), 141 (M-59); Yield (%): 20; Elemental analysis (%): 
Calcd.: C, 53.88; H, 4.52. Found: C, 53.65; H, 4.63. 
9.  3-Hydroxy-2,2-dimethyl-(4-methoxyphenyl)butanoic acid; C13H18O4; Mw = 238.28; Melting 
point: 120 oC; IR (KBr): ν max (cm-1) 3420 (ν , -C(O)-OH), 2996 (ν , -C(O)-OH), 1728 (ν , 
>C=O),1251 (ν , -C-O); 1H NMR (CDCl 3) (δ): 1.12 (s, 3 H); 1.15 (s, 3 H); 1.64 (s, 3 H); 3.79 (s, 3 H); 
6.81-7.37 (m, 4 H); 13C NMR (CDCl 3) (δ): 21.56 (-C(CH3)2-); 25.13 (-C(OH)CH3-); 50.11 (-C(CH3)2-
); 55.13 (CH3-O-Ar); 77.18 (-C(OH)CH3-); 112.70 (m-Ar); 128.32 (o-Ar); 134.72 (C-OCH3); 158.59 
(Cipso); 182.67 (COOH); MS (CI) 239 (M+H)
+, 221 (M-18), 151 (M-87); Yield (%): 45; Elemental 
analysis (%): Calcd.: C, 65.53; H, 7.61. Found: C, 65.76; H, 7.94. 
10.  2-Hethyl-2-(1-(1-hydroxycyclohexyl))propanoic acid; C10H18O3; Mw = 186.25; Melting 
point: 89 oC; IR (KBr) : ν max (cm-1) 3497 (ν , -CH-OH), 3411 (ν , -C(O)-OH), 2970 (ν , -C(O)-OH), 
1686 (ν , >C=O), 1144 (ν , -C-O); 1H NMR (CDCl 3) (δ) : 1.25 (s, 6 H); 1.21-1.69 (m, 10 H); 13C 
NMR (CDCl 3) (δ): 20.74 (-C(CH3)2-); 21.41 ( 2’(4’)-CH2-); 25.53 (4’-CH2-); 31.30 (2’(6’)-CH2-); 
50.11 (-C(CH3)2-); 74.63 (C-OH); 183.09 (COOH); MS (CI) 187 (M+H)
+, 169 (M-17); Yield (%): 28; 
Elemental analysis (%): Calcd.: C, 64.49; H, 9.74. Found: C, 64.20; H, 10.02. 
11.  3-Hydroxy-2,2-dimethyl-3-phenylbutanoic acid; C12H16O3; Mw = 208.26; Melting point: 89 
oC; IR (KBr) : ν max (cm-1) 3230 (ν , -CH-OH), 3205, (ν , -C(O)-OH), 2989 (ν , -C(O)-OH), 1723 (ν , 
>C=O), 1159 (ν , -C-O); 1H NMR (CDCl 3) (δ): 1.13 (s, 3 H); 1.16 (s, 3 H); 1.66 (s, 3 H); 7.25-7.46 
(m, 5 H); 13C NMR (DMSO) (δ) 21.54 (-C(CH3)2-); 21.59 (-C(CH3)2-); 25.00 (-C(OH)CH3-); 49.98 (-
C(CH3)2-); 77.38 (-C(OH)CH3-); 127.12 (o-Ph); 127.23 (p-Ph); 127.43 (m-Ph); 142.52 (Cipso-Ph); 
182.98 (COOH); MS (CI) 208 (M+), 191 (M-17), 121 (M-87); Yield (%): 33; Elemental analysis 
(%) : Calcd.: C, 69.21; H, 7.77. Found: C, 68.97; H, 7.74. 
12.  3-Hydroxy-3(4-isobutylphenyl)butanoic acid;C14H20O3; Mw = 236.31; Melting point : 90 
oC; 
IR (KBr):  ν max (cm-1) 3515, 3400 (ν , -C(O)-OH), 2957 (ν , -C(O)-OH), 1683 (ν , >C=O), 1244 (ν , -
C-O); 1H NMR (CDCl 3) (δ): 0.87 (d, J 6.6 Hz, 3H); 0.90 (d, J 6.6 Hz, 3H); 1.55 (s, 3H); 1.85 (h, 1 H); 
2.45 (d, J 7.2 Hz, 2 H); 2.91 (dd, J 16 Hz, J 39.2 Hz, 2 H); 5.76 (b, OH); 7.10 (d, J 8 Hz) 7.30 (d, J 8 
Hz); 13C NMR (CDCl 3) (δ): 22.34 (-CH(CH3)2); 30.10 (-CH(CH3)2); 30.39 (CH3-C(OH)-); 44.88 (Ar-
CH2-); 46.08 (-CH2-COOH); 72.74 (CH3-C(OH)-); 124.06 (o-Ph); 129.09 (m-Ph); 140.51 (Cipso-i-Bu); 




143.57 (Cipso); 176.98 (COOH); MS (CI)  236 (M+), 218 (M-18), 177 (M-59); Yield (%): 42; 
Elemental analysis (%): Calcd.: C, 70.11; H, 8.53; Found: C, 70.08; H, 8.58. (with 0.2 mol H2O; in 
1H NMR spectra, presence of water is observed) 
13.  3-Hydroxy-2,2-dimethyl-3-phenylpropanoic acid; C11H14O3; Mw = 194.23; Melting point: 
132 0C; IR (KBr):  ν max (cm-1) 3439, 3380 (ν , -OH), 2984 (ν , -C(O)-OH), 1707 (ν , >C=O), 1134 
(ν , -C-O); 1H NMR (CDCl 3) (δ) 1.17 (s, 6 H); 4.96 (s, 1 H); 7.32-7.36 (m, 5 H); 13C NMR (CDCl 3) 
(δ) 18.50 (-C(CH3)2-); 23.29 (-C(CH3)2-); 47.49 (-C(CH3)2-); 78.47 (HO-CH(Ph)-); 127.72 (o-Ph); 
127.96 (m-Ph); 128.07 (p-Ph); 139.47 (Cipso-Ph); 182.80 (COOH); MS (CI). 194 (M
+), 176 (M-18), 
107 (M-87); Yield (%): 25; Elemental analysis (%): Calcd.: C, 68.02; H, 7.26; Found: C, 67.71; H, 
7.55. 
14.  3-Hydroxy-3,3-diphenylpropanoic acid; C15H14O3; Mw = 242.09; Melting point: 217 
0C; IR 
(KBr):  ν max (cm-1) 3478 (ν , -OH), 2908 (ν , -C(O)-OH), 1688 (ν , >C=O), 1232 (ν , -C-O); 1H NMR 
(DMSO) (δ) 3.28 (s, 2 H); 7.12-7.48 (m, 10 H); 13C NMR (DMSO) (δ) 45.33 (-CH2-COOH); 75.71 
(HO-C(Ph)2-); 125.69 (o-Ph); 126.60 (p-Ph); 128.07 (m-Ph); 147.54 (Cipso-Ph); 173.35 (COOH); MS 
(CI) . 242 (M+) 183 (M-59); Yield (%): 40; Elemental analysis (%): Calcd.: C, 74.36; H,. 5.82; 
Found: C, 74.22; H, 6.01. 
15.  2-(1’-(1’-Hydroxycyclohexyl))butanoic acid; C10H18O3; Mw = 186.25; Melting point: 86 
0C; 
IR (KBr):  ν max (cm-1) 3384 (ν ,-OH), 2936 (ν , -C(O)-OH), 1710 (ν , >C=O), 1193 (ν , -C-O); 
1HNMR (CDCl 3) (δ) 0.97 (t, J 7.3 Hz. 3H); 1.22-1.81 (m, 12H); 2.38 (t, J 7.5 Hz, 3H); 13C NMR 
(CDCl3) (δ) 12.32 (-CH2-CH3); 19.41(-CH2-CH3) ; 21.59 (3’(5’)-CH2); 21.79 (5’(3’)-CH2); 25.51 (4’-
CH2); 34.19 (2’(6’)-CH2); 37.11 (6’(2’)-CH2); 56.48 (-CH(Et)COOH); 71.96 (1’-COH); 181.00 
(COOH); (MS (CI)  186 (M+), 169 (M-17), 100 (M-87); Yield (%): 40; Elemental analysis (%): 
Calcd.: C, 64.49; H, 9.74; Found: C, 64.23; H, 9.86. 
3.2. Cell culture 
Human: colon carcinoma LS174, cervix carcinoma HeLa, and melanoma Fem-X cells, were 
cultured as monolayers in the nutrient medium. Human myelogenous leukemia K562 cells were 
maintained as suspension culture. Nutrient medium was RPMI 1640 medium, supplemented with L-
glutamine (3 mM), streptomycin (100 µg/ml), and penicillin (100 UI/mL), 10% heat inactivated (56 
0C) fetal bovine serum (FBS) and 25 mM Hepes, and was adjusted to pH 7.2 by bicarbonate solution. 
The cells were grown at 37 oC in 5% CO2 and humidified air atmosphere. 
 
3.2.1. Investigated compounds 
Stock solutions of 15 acids, in concentrations of 20 mM in DMSO, were diluted in nutrient medium 
to get final concentration in the range from 0-300 µM. 
 
3.2.2. Preparation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMC) were separated from whole heparinized blood of two 
healthy volunteers by LymphoprepTM (Oslo, Norway) gradient centrifugation. Cells, washed three times 




with Haemaccel (aqueous solution supplemented with 145 mM Na+, 5.1 mM K+, 6.2 mM Ca+, 145 mM 
Cl−, and 35 g/L gelatin polymers, pH=7.4) were counted and resuspended in nutrient medium. 
 
3.2.3. Treatment of LS174, HeLa, Fem-x and K562 cells 
Neoplastic LS174 cells were seeded (6,000 cells per well), while HeLa and Fem-X cells were 
seeded at density of 2,000 cells per well, into 96-well microtiter plates, and 20 h later, after the cell 
adherence, five different, double diluted, concentrations of investigated compounds were added to the 
wells. Only to 3,000 per well of K562 cells, investigated compounds were added 2h after the cell 
seeding. 
 
3.2.4. Treatment of PBMC 
PBMC Were seeded (150,000 cells per well), into nutrient medium without, or enriched with 
(5µg/ml) phytohaemaglutinin (PHA) (Welcome) in 96-well microtiter plates. Two hours later, 
investigated extracts were added to the wells, in triplicate, to five final concentrations, except to the 
control wells where only a nutrient medium was added to the cells. Nutrient medium with 
corresponding concentrations of compounds, but void of cells was used as the blank. 
 
3.2.5. Determination of cell survival 
Cell survival was determined indirectly by measuring total protein by the Kenacid Blue R (KBR) 
dye binding method [19]. Briefly, after 72 h of continuous agent’s action, medium was discarded and 
target cells were washed twice with warm (37 oC) phosphate buffered saline (PBS). PBMC were 
always centrifuged 10 min at 2.000 rpm and supernatant was aspirated, leaving a small amount of 
medium, just to not disturb cells in the pellet. Then target cells were fixed for 20 min with 150 µl of a
mixture of methanol and acetic acid (3:1) and stained 2-3 h with 0.04% Coomassie Brilliant Blue R-
250 in 25% ethanol and 12% glacial acetic acid, washed, and bound dye was dissolved in desorbing 
solution (1M potassium acetate, 70% ethanol). Absorbance (A) at 570 nm was measured 2h later. To 
get cell survival (%), A of a sample with cells grown in the presence of various concentrations of the 
investigated agent was divided with control optical density (the A of control cells grown only in 
nutrient medium), and multiplied by 100. It was implied that A of the blank was always subtracted 
from A of the concentration of the corresponding sample with target cells. IC50 concentration was 
defined as the concentration of an agent inhibiting cell survival by 50%, compared with a vehicle-
treated control. 
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